Poly Medicure Limited , a prominent player in the medical devices industry, has made significant strides in expanding its global presence through strategic acquisitions. The company has recently approved the purchase of Medistream SA and its subsidiaries through its Netherlands-based entity, Poly Medicure B.V. This move will result in Poly Medicure gaining full ownership of the Citieffe Group.

Citieffe Group Acquisition Details

Poly Medicure has acquired 100% of Citieffe Group, a vertically integrated trauma and extremity fixation systems company founded in 1962. The acquisition involves:

Citieffe reported impressive financial performance:

Key highlights of Citieffe Group:

• Manufacturing facilities in Bologna, Italy
• Direct sales presence in Italy, USA, and Mexico
• 85% of revenue generated from these markets
• 45 patents
• 12% market share as the #2 independent player in Italy's trauma market

The transaction will be funded through cash balances and internal accruals, with closure expected within 4-8 weeks. Existing management, including CEO Pascal Govi, will continue post-acquisition.

Strategic Implications

These acquisitions underscore Poly Medicure's commitment to expanding its global footprint and diversifying its product portfolio. The Citieffe Group acquisition provides Poly Medicure entry into the global orthopaedic market, particularly the trauma and extremities segment valued at $12 billion globally.

Recent Expansion Activities

This latest acquisition follows closely on the heels of another significant transaction by Poly Medicure. According to the company's recent LODR (Listing Obligations and Disclosure Requirements) filing, Poly Medicure has also completed the acquisition of the PendraCare Group through its wholly-owned step-down subsidiary, RisoR Holdings B.V.

PendraCare Group Acquisition Highlights

• Date of Completion: September 23, 2025
• Acquired Entities: Pendracare Holdings B.V. and Wellinq Medical B.V. (collectively known as the PendraCare Group)
• Ownership Structure: Poly Medicure, through RisoR Holding B.V., now owns 90% of the economic rights in the PendraCare Group
• Transaction Type: Share Purchase Agreement (SPA) with Wellinq Holdings B.V.

Compliance and Disclosure

Poly Medicure has ensured compliance with regulatory requirements by promptly disclosing the details of these acquisitions to the stock exchanges. The company has adhered to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and related SEBI circulars in reporting these significant corporate actions.

Investor Conference Call

To further discuss the proposed acquisition of Citieffe Group, Poly Medicure has scheduled an investor and analyst conference call for September 25, 2025 at 4:00 PM India time. The call will be represented by Managing Director Himanshu Baid and President of Strategy & Corporate Development Rahul Gautam. The company has provided dial-in details and registration links for participants to join the discussion.

As Poly Medicure continues to execute its growth strategy through these strategic acquisitions, stakeholders will be keenly watching how these moves translate into enhanced value and market presence for the company in the competitive medical devices sector.

Poly Medicure Limited , a prominent player in the medical devices industry, has successfully completed the acquisition of the PendraCare Group, marking a significant expansion in its global footprint. The company announced the closure of the deal through its wholly-owned step-down subsidiary, RisoR Holdings B.V., based in Amsterdam, Netherlands.

Acquisition Details

The acquisition has now been finalized with all conditions of the Share Purchase Agreement (SPA) fulfilled. Key points of the transaction include:

• Poly Medicure now owns 90% of the economic rights in the PendraCare Group.
• The acquisition was executed through RisoR Holdings B.V., a wholly-owned step-down subsidiary of Poly Medicure Limited.
• Wellinq Medical B.V. and PendraCare Holding B.V. have become step-down subsidiaries of Poly Medicure Limited.
• The SPA was signed between RisoR Holdings B.V. and Wellinq Holdings B.V., both based in Amsterdam, Netherlands.

Strategic Implications

This acquisition represents a strategic move for Poly Medicure Limited, potentially enhancing its product portfolio and market presence in Europe. The PendraCare Group's integration into Poly Medicure's operations is expected to bring synergies and expand the company's capabilities in the medical devices sector.

Regulatory Compliance

In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Poly Medicure Limited has duly informed the stock exchanges about the completion of this acquisition. The company stated that all necessary disclosures regarding the acquisition details were previously made in their intimation letter.

Conclusion

The successful completion of this acquisition marks a significant milestone for Poly Medicure Limited. As the company integrates the PendraCare Group into its operations, stakeholders will be keen to observe the impact on Poly Medicure's market position and financial performance in the coming quarters.

Investors and market watchers are advised to keep an eye on future announcements from Poly Medicure Limited for updates on the integration process and potential business synergies resulting from this strategic acquisition.